VALN - Valneva Says Single Chikungunya Vaccine Shows Long-Lasting Antibody Response In Younger Older Adults | Benzinga
Valneva SE (NASDAQ: VALN) reported antibody persistence data 24 months after vaccination with a single dose of its chikungunya vaccine IXCHIQ, further supporting the anticipated long-term durability of the immune response and in line with positive twelve-month persistence data the company reported in December 2022.
Valneva was granted FDA approval for its chikungunya vaccine IXCHIQ in November 2023.
These persistence ...